GNLXGENELUX Corp同业对比
GENELUX Corp 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GNLX本股 | $114M#8 | — | 7.1x#11 | 14308.8x#8 | 0.0%#5 | -7.6%#7 | -415175.0%#8 | -199.5%#13 | -424.2%#5 | — | -35.5%#10 | — |
| HURA | $133M#1 | — | 7.2x#12 | — | — | -34.8%#10 | — | -167.6%#12 | -0.1%#1 | — | -16.1%#8 | — |
| BMEA | $129M#2 | — | 10.7x#14 | — | — | 55.4%#4 | — | -509.2%#14 | — | — | -8.7%#6 | — |
| INO | $125M#3 | — | 28.6x#15 | 1914.7x#6 | -70.0%#8 | 20.6%#5 | -132871.3%#6 | -1944.6%#15 | -243.9%#3 | — | -44.4%#12 | — |
| AARD | $122M#4 | — | 1.6x#3 | — | — | -179.7%#14 | — | -77.0%#9 | — | — | -49.3%#13 | — |
| EQ | $120M#5 | — | 2.1x#4 | 2.9x#2 | 13.9%#4 | -177.6%#13 | -57.5%#2 | -40.0%#5 | -368.9%#4 | — | 23.5%#3 | — |
| OKUR | $119M#6 | — | 0.7x#1 | — | — | -13.0%#8 | — | -34.6%#4 | — | — | 21.9%#4 | — |
| PMN | $119M#7 | — | 2.4x#6 | — | — | -1529.3%#16 | — | -80.4%#10 | — | — | 19.9%#5 | — |
| MIST | $114M#9 | — | 6.3x#9 | — | — | -51.9%#12 | — | -0.3%#1 | — | — | -52.7%#14 | — |
| COYA | $111M#10 | — | 2.6x#7 | 14.0x#3 | 123.6%#1 | -42.6%#11 | -283.9%#3 | -49.0%#6 | — | — | -12.2%#7 | — |
| CPIX | $106M#11 | — | 6.1x#8 | 2.4x#1 | 17.6%#3 | 56.2%#3 | -6.3%#1 | -16.3%#3 | — | — | 114.5%#2 | — |
| PLYX | $101M#12 | — | 9.3x#13 | — | — | 70.4%#2 | — | -82.1%#11 | — | — | — | — |
| CTOR | $96M#13 | — | 2.4x#5 | — | — | -17.1%#9 | — | -61.3%#7 | — | — | -43.0%#11 | — |
| ANIX | $95M#14 | — | 6.6x#10 | 454.4x#5 | 0.0%#5 | 13.0%#6 | -5571.9%#5 | -75.5%#8 | -87.0%#2 | — | -18.5%#9 | — |
| RLYB | $89M#15 | 3.4x#1 | 0.9x#2 | 104.0x#4 | 34.9%#2 | 84.5%#1 | -3853.6%#4 | -9.5%#2 | — | — | 265.6%#1 | — |
| NTHI | $87M#16 | — | — | 2185.7x#7 | -51.8%#7 | -422.3%#15 | -145637.5%#7 | — | — | — | -68.2%#15 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议